Chronic inflammation, immune escape, and oncogenesis in the liver: A unique neighborhood for novel intersections
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Sustained hepatic inflammation, driven by alcohol consumption, nonalcoholic fatty liver disease, and/or chronic viral hepatitis (hepatitis B and C), results in damage to parenchyma, oxidative stress, and compensatory regeneration/proliferation. There is substantial evidence linking these inflammation-associated events with the increased incidence of hepatocellular carcinogenesis. Although acute liver inflammation can play a vital and beneficial role in response to liver damage or acute infection, the effects of chronic liver inflammation, including liver fibrosis and cirrhosis, are sufficient in a fraction of individuals to initiate the process of transformation and the development of hepatocellular carcinoma. This review highlights immune-dependent mechanisms that may be associated with hepatocellular oncogenesis, including critical transformative events/pathways in the context of chronic inflammation and subverted tolerogenesis. (Hepatology 2012)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 2×
“Furthermore, the negative costimulatory receptor PD1, expressed primarily on T cells and B cells, inhibits antigen-specific CD8þ T cell activation/memory and inflammatory hepatitis.(31) Expression of PD-1 ligands, PD-L1 and PD-L2, is elevated in steady-state liver, with highest levels of expression on KC, infiltrating…”
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · cited 7×
“In liver, (oncogene-induced) senescent hepatocytes also secrete CTACK, IL-1a, leptin/leptin R, MCP1, and RANTES.(19) Noninitiated bystander cells including immune cells can reinforce this program by also secreting prosenescent cytokines.”
InfluentialIliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Crispe, I. N. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132629 · Cited by 986 · cited 2×
“Expression of PD-1 ligands, PD-L1 and PD-L2, is elevated in steady-state liver, with highest levels of expression on KC, infiltrating macrophages, liver sinusoidal endothelial cells (LSECs), dendritic cells, and parenchymal cells.(32) Increased expression of the inhibitory receptor, PD-1, and/or interactions with its…”
Liver: An organ with predominant innate immunity
Gao, B., Jeong, W.-I., & Tian, Z. (2008) · Hepatology · doi:10.1002/hep.22034 · Cited by 952
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758 · cited 2×
“MDSCs are a heterogeneous population of immature myeloid cells, which can expand and contribute to immune suppression during HCV infection and HCC.37,38 The liver is a preferred site for homing and expansion of MDSCs.39 MDSCs can disrupt immune surveillance mechanisms including suppressing effector T cells,38 expandin…”
Sakurai, T., He, G., Matsuzawa, A., Yu, G.-Y., Maeda, S., Hardiman, G., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.016 · Cited by 487
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Jeong, W.-I., Park, O., Suh, Y.-G., Byun, J.-S., Park, S.-Y., Choi, E., Kim, J.-K., Ko, H., Wang, H., Miller, A. M., et al. (2011) · Hepatology · doi:10.1002/hep.24190 · Cited by 142
T cell-derived lymphotoxin regulates liver regeneration
Tumanov, A. V., Koroleva, E. P., Christiansen, P. A., Khan, M. A., Ruddy, M. J., Burnette, B., Papa, S., Franzoso, G., Nedospasov, S. A., Fu, Y., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.015 · Cited by 89
Cited by
The Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3458 · Cited by 1,842
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 616
Yu, Z., Guo, J., Hu, M., Gao, Y., & Huang, L. (2020) · ACS Nano · doi:10.1021/acsnano.0c00708 · Cited by 433
Hepatocellular carcinoma in the setting of alcohol-related liver disease
Ganne-Carrié, N., & Nahon, P. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.008 · Cited by 360
Baeck, C., Wei, X., Bartneck, M., Fech, V., Heymann, F., Gassler, N., Hittatiya, K., Eulberg, D., Luedde, T., Trautwein, C., et al. (2014) · Hepatology · doi:10.1002/hep.26783 · Cited by 270
“Overall, the perpetuation of inflammation, as reflected by proinflammatory cytokine levels in the liver, appears to counteract regenerative processes and degradation of ECM, thus inhibiting resolution of fibrosis.(31) Translating the findings from murine models into human pathogenesis is hampered by the fact that muri…”
Background
Metadata
- Authors
- Stauffer, J. K., Scarzello, A. J., Jiang, Q., & Wiltrout, R. H.
- Venue
- Hepatology
- Published
- 2012-10
- Volume
- 56
- Issue
- 4
- Pages
- 1567-1574
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2055104815
- Cited by
- 135
- References
- 12
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.